WO2004037768A2 - Composes a usage medicinal - Google Patents
Composes a usage medicinal Download PDFInfo
- Publication number
- WO2004037768A2 WO2004037768A2 PCT/EP2003/012038 EP0312038W WO2004037768A2 WO 2004037768 A2 WO2004037768 A2 WO 2004037768A2 EP 0312038 W EP0312038 W EP 0312038W WO 2004037768 A2 WO2004037768 A2 WO 2004037768A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- compound
- hydrogen
- solvate
- Prior art date
Links
- 0 CC1*(C)N(C)C1C Chemical compound CC1*(C)N(C)C1C 0.000 description 2
- AAIJEURQKZASKQ-UHFFFAOYSA-N Cc(cc1)cc(C)c1F Chemical compound Cc(cc1)cc(C)c1F AAIJEURQKZASKQ-UHFFFAOYSA-N 0.000 description 1
- KUFFULVDNCHOFZ-UHFFFAOYSA-N Cc(cc1)cc(C)c1O Chemical compound Cc(cc1)cc(C)c1O KUFFULVDNCHOFZ-UHFFFAOYSA-N 0.000 description 1
- OIPPWFOQEKKFEE-UHFFFAOYSA-N Cc1cc(O)cc(O)c1 Chemical compound Cc1cc(O)cc(O)c1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Definitions
- the present invention is concerned with phenethanolamine derivatives, processes for their preparation, compositions containing them and their use in medicine, particularly in the prophylaxis and treatment of respiratory diseases.
- phenethanolamine compounds are known in the art as having selective stimulant action at ⁇ radrenoreceptors and therefore having utility in the treatment of bronchial asthma and related disorders.
- GB 2 140 800 describes phenethanolamine compounds including 4-hydroxy- ⁇ 1 -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1 ,3- benzenedimethanol 1-hydroxy-2-naphthalenecarboxylate (salmeterol xinafoate) which is now used clinically in the treatment of such medical conditions.
- n is an integer of from 2 to 10, preferably from 2 to 6; with the proviso that m + n is 5 to 19, preferably 5 to 12;
- R 1 is selected from hydrogen, C h alky!, hydroxy, d-ealkoxy, cyano, nitro, halo, C ⁇ haloalkyl, -XNR 8 C(O)R 9 , -XNR 8 C(O)NR 9 R 10 , -XNR 8 C(O)NC(O)NR 9 R 10 , -XNR 8 SO 2 R 9 ,
- R 1 is selected from -X-aryl, -X-hetaryl, or -X-(aryloxy), each optionally substituted by 1 or 2 groups independently selected from hydroxy, C ⁇ alkoxy, halo, C ⁇ alkyl,
- X is -(CH 2 ) r - or C 2 -e alkenylene
- r is an integer from 0 to 6, preferably 0 to 4;
- R 8 and R 9 are independently selected from hydrogen, C ⁇ alkyl, C 3 - 7 cycloalkyl, aryl, hetaryl, hetary d- ⁇ alkyl)- and ary C ⁇ alkyl)- and R 8 and R 9 are each independently optionally substituted by 1 or 2 groups independently selected from halo, C ⁇ alkyl, C 3 - 7 cycloalkyl, C,.
- R 1 is -XNR 8 C(O)NR 9 R 10 , R 8 and R 9 may, together with the -NC(O)N- portion of the group R 1 to which they are bonded, form a saturated or unsaturated ring, preferably a 5-, 6-, or 7- membered ring, for example an imidazolidine ring, such as imidazolidine-2,4- dione;
- R 1 is -XNR 8 C(O)OR 9
- R 8 and R 9 may, together with the -NC(O)O- portion of the group R 1 to which they are bonded, form a saturated or unsaturated ring, preferably a 5-, 6-, or 7- membered ring, for example an oxazolidine ring, such as oxazolidine-2,4-dione;
- R 1 ⁇ is selected from hydrogen, C ⁇ alkyl and C 3 - 7 cycloalkyl; or where R 1 contains a moiety -NR 9 R 10 , R 9 and R 10 may, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7- membered nitrogen containing ring;
- R 2 and R 3 are each independently selected from hydrogen, hydroxy, C ⁇ alkyl, C ⁇ - 6 alkoxy, halo, aryl, aryl(C ⁇ alkyl)-, C ⁇ haloalkoxy, and C ⁇ haloalkyl;
- R 4 and R 5 are independently selected from hydrogen and C ⁇ alkyl with the proviso that the total number of carbon atoms in R 4 and R 5 is not more than 4;
- R 6 and R 7 represents hydrogen or C 1j4 alkyl and the other of R 6 and R 7 represents C ⁇ alkyl, or R 6 and R 7 , together with the carbon atom to which they are bonded, form a C 3 . 7 cycloalkyl ring;
- Ar 1 is a group selected from
- R 11 represents hydrogen, halogen, -(CH 2 ) q OR 15 , -NR 15 C(O)R 16 , -NR 15 SO 2 R 16 , -SO 2 NR 15 R 16 , -NR 15 R 16 , -OC(O)R 17 or OC(O)NR 15 R 16
- R 12 represents hydrogen, halogen or C- 1 - 4 alkyl; or R 11 represents -NHR 18 and R 12 and -NHR 18 together form a 5- or 6- membered heterocyclic ring;
- R 13 represents hydrogen, halogen, -OR 15 or -NR 15 R 16 ;
- R 14 represents hydrogen, halogen, haloC,.-, alkyl, -OR 15 , -NR 15 R 16 , -OC(O)R 17 or OC(O)NR 15 R 16 ;
- R 15 and R 16 each independently represents hydrogen or C 1 -- 1 alkyl, or in the groups - NR 15 R 16 , -SO 2 NR 15 R 16 and -OC(O)NR 15 R 16 , R 15 and R 16 independently represent hydrogen or C ⁇ alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,
- R 17 represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, C- alkyl, hydroxy, C alkoxy or halo C alkyl; and
- q is zero or an integer from 1 to 4.
- the present invention provides a compound of formula (I) as defined hereinabove, or a salt, solvate or physiologically functional derivative thereof, except that R 11 does not represent hydrogen.
- the group R 1 is preferably selected from hydrogen, -XNR 8 C(0)NR 9 R 1 °, or -XSO 2 NR 9 R 10 .
- alkenylene includes both cis and trans structures.
- X is preferably (CH 2 ) r , where r is 0 to 2, or C 2 -alkenylene.
- the group R 1 is preferably attached to the meta-position relative to the -O-(CH 2 ) n - link.
- R 4 and R 5 are preferably independently selected from hydrogen and methyl, more preferably R 4 and R 5 are both hydrogen.
- one of R 6 and R 7 is selected from hydrogen and methyl and the other of R 6 and R 7 represents methyl.
- n is suitably 4, 5, or 6, and n is suitably 2, 3, 4, or 5.
- m is 5 or 6 and n is 2 or 3, such that m + n is 7,8 or 9 preferably 8.
- the group Ar 1 is preferably selected from groups (a) and
- R 11 represents halogen this is preferably chlorine or fluorine.
- R 15 and R 16 preferably each independently represent hydrogen or methyl.
- R 17 preferably represents substituted phenyl.
- the integer q preferably represents zero or 1.
- OR 15 preferably represents OH or -CH 2 OH;
- NR 15 C(O)R 16 preferably represents -NHC(O)H
- -SO 2 NR 15 R 16 preferably represents -SO 2 NH 2 or SO 2 NHCH 3 ; NR 15 R 16 preferably represents -NH 2 ;
- -OC(O)R 17 preferably represents substituted benzoyloxy eg. OC(O)-C 6 H 4 -(p-CH 3 );
- R 15 R 18 preferably represents OC(O)N(CH 3 ) 2 .
- R 11 represents NHR 18 and together with R 12 forms a 5- or 6- membered heterocyclic ring -NHR 18 -R 12 - preferably represents a group:
- R 19 is an alkyl, alkenyl or alkyloxy group
- R 20 is an alkyloxy group
- R 21 is an alkyl or alkenyl group optionally substituted by COOR 22 where
- R 22 is C M alkyl; or NH-CO-S-; wherein said alkyl and alkenyl groups and moieties contain 1 or 2 carbon atoms.
- Particularly preferred groups (a) and (b) may be selected from the following groups (i) to (xxi):
- Ar 1 is a group (i):
- Preferred compounds of the .invention include:
- the compounds may therefore exist in two different enatiomeric forms.
- the present invention includes both (S) and (R) enantiomers at both chiral centres either in substantially pure form or admixed in any proportions.
- R 4 and R 5 are different groups, or where R 6 and R 7 are different groups the carbon atom to which they are attached is an asymmetric centre and the present invention includes both (S) and (R) enantiomers at this centre either in substantially pure form or admixed in any proportions.
- the compounds of formula (I) include all enantiomers and diastereoisomers as well as mixtures thereof in any proportions.
- Salts and solvates of compounds of formula (I) which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable.
- salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of formula (I) and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives.
- physiologically functional derivative is meant a chemical derivative of a compound of formula (I) having the same physiological function as the parent compound of formula (I) for example, by being convertible in the body thereto.
- physiologically functional derivatives include esters.
- Suitable salts according to the invention include those formed with both organic and inorganic acids or bases.
- Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulphamic, sulphanilic, succinic, oxalic, fumaric, maleic, malic, glutamic, aspartic, oxaloacetic, methanesulphonic, ethanesulphonic, arylsulphonic (for example p-toluenesulphonic, benzenesulphonic, naphthalenesulphonic or naphthalenedisulphonic), salicylic, glutaric, gluconic, tricarballylic, cinnamic, substituted cinnamic (for example, phenyl, methyl , methoxy or halo substituted
- Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexyl amine and N-methyl-D-glucamine.
- esters of the compounds of formula (I) may have a hydroxyl group converted to a C h alky!, aryl, aryl d-e alkyl, or amino acid ester. .
- the compounds of formula (I) are selective ⁇ 2 -adrenoreceptor agonists as demonstrated using functional or reporter gene readout from cell lines transfected with human beta-adrenoreceptors as described below.
- Compounds according to the present invention also have the potential to combine long duration of effect with rapid onset of action.
- certain compounds have shown an - improved therapeutic index in animal models relative to existing long-acting ⁇ 2 -agonist bronchodilators. As such, compounds of the invention may be suitable for once-daily administration.
- Compounds of formula (I) and their pharmaceutically acceptable salts, solvates, and physiologically functional derivatives have use in the prophylaxis and treatment of clinical conditions for which a selective ⁇ 2 -adrenoreceptor agonist is indicated.
- Such conditions include diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).
- COPD chronic obstructive pulmonary diseases
- rhinitis e.g. chronic and whez bronchitis, emphysema
- respiratory tract infection e.g. rhinitis, including seasonal and allergic rhinitis.
- Other conditions which may be treated include premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) and muscle wasting disease.
- skin diseases e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases
- conditions where lowering peptic acidity is desirable e.g. peptic and gastric ulceration
- muscle wasting disease e.g. peptic and gastric ulceration
- the present invention provides a method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective ⁇ 2 -adrenoreceptor agonist is indicated, which comprises administration of a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
- a mammal such as a human
- the present invention provides such a method for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
- COPD chronic obstructive pulmonary disease
- the present invention provides such a method for the prophylaxis or treatment of a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) or muscle wasting disease.
- a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) or muscle wasting disease.
- a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in medical therapy, particularly, for use in the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which a selective ⁇ 2 -adrenoreceptor agonist is indicated.
- a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the prophylaxis or treatment of a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
- COPD chronic obstructive pulmonary disease
- a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the prophylaxis or treatment of a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) or muscle wasting disease.
- a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) or muscle wasting disease.
- the present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which a selective ⁇ 2 -adrenoreceptor agonist is indicated, for example a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
- a disease associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease.
- COPD chronic obstructive pulmonary disease
- a clinical condition selected from premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) and muscle wasting disease.
- the amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the subject under treatment, and the particular disorder or disease being treated.
- the compounds of the invention may be administered by inhalation at a dose of from 0.0005mg to 10 mg, preferably O.OO ⁇ mg to 0.5mg, eg. 0.05mg to 0.5mg.
- the dose range for adult humans is generally from 0.0005 mg to 10mg per day and preferably 0.01 mg to 1 mg per day, most preferably 0.05mg to 0.5mg per day.
- the present invention further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
- active ingredient means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
- the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), inhalation (including fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers or insufflators), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
- formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water- in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
- Powder blend formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier/diluent/excipient substance) such as mono-, di or poly- saccharides (eg. lactose or starch). Use of lactose is preferred.
- Each capsule or cartridge may generally contain between 20 ⁇ g-10mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient.
- the compound of the invention may be presented without excipients.
- Packaging of the formulation may be suitable for unit dose or multi-dose delivery. In the case of multi-dose delivery, the formulation can be pre-metered (eg as in Diskus, see GB 2242134, US Patent Nos.
- the Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed
- each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose.
- the strip is sufficiently flexible to be wound into a roll.
- the lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width.
- the lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.
- Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant.
- Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the compound of formula (I) optionally in combination with another therapeutically active ingredient and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g.
- the aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosolvents eg ethanol.
- Pressurised formulations will generally be retained in a canister (eg an aluminium canister) closed with a valve (eg a metering valve) and fitted into an actuator provided with a mouthpiece.
- Medicaments for administration by inhalation desirably have a controlled particle size.
- the optimum particle size for inhalation into the bronchial system is usually 1-1 O ⁇ m, preferably 2-5 ⁇ m.
- Particles having a size above 20 ⁇ m are generally too large when inhaled to reach the small airways.
- the particles of the active ingredient as produced may be size reduced by conventional means eg by micronisation.
- the desired fraction may be separated out by air classification or sieving.
- the particles will be crystalline.
- the particle size of the excipient will be much greater than the inhaled medicament within the present invention.
- the excipient is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD of 60-90 ⁇ m and not less than 15% will have a MMD of less than 15 ⁇ m.
- Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
- agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
- Solutions for inhalation by nebulation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.
- Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
- Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose an acacia.
- Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
- the compounds and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from anti-inflammatory agents, anticholinergic agents (particularly an M ⁇ M 2 , M ⁇ /M 2 or M 3 receptor antagonist), other ⁇ 2 -adrenoreceptor agonists, antiinfective agents (e.g. antibiotics, antivirals), or antihistamines.
- anti-inflammatory agents particularly an M ⁇ M 2 , M ⁇ /M 2 or M 3 receptor antagonist
- antiinfective agents e.g. antibiotics, antivirals
- antihistamines e.g. antibiotics, antivirals
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with one or more other therapeutically active agents, for example selected from an anti-inflammatory agent (for example a corticosteroid or an NSAID), an anticholinergic agent, another ⁇ 2 - adrenoreceptor agonist, an antiinfective agent (e.g. an antibiotic or an antiviral), or an antihistamine.
- an anti-inflammatory agent for example a corticosteroid or an NSAID
- an anticholinergic agent for example a corticosteroid or an NSAID
- an antiinfective agent e.g. an antibiotic or an antiviral
- Preferred combinations comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a corticosteroid, and/or an anticholinergic, and/or a PDE-4 inhibitor.
- the other therapeutic ingredient(s) may be used in the form of salts, (e.g. as alkali metal or amine salts or as acid addition salts), or prodrugs, or as esters (e.g. lower alkyl esters), or as solvates (e.g. hydrates) to optimise the activity and/or stability and/or physical characteristics (e.g. solubility) of the therapeutic ingredient.
- the therapeutic ingredients may be used in optically pure form.
- Suitable anti-inflammatory agents include corticosteroids and NSAIDs.
- Suitable corticosteroids which may be used in combination with the compounds of the invention are those oral and inhaled corticosteroids and their pro-drugs which have anti- inflammatory activity. Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ - hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester, 6 ⁇ ,9 ⁇ -difluoro-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-17 ⁇ -propionyloxy- androsta-1,4-diene-17 ⁇ - carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester, beclomethasone esters (e
- the 17-propionate ester or the 17,21-dipropionate ester the 17-propionate ester or the 17,21-dipropionate ester
- budesonide flunisolide
- mometasone esters e.g. the furoate ester
- triamcinolone acetonide e.g. the furoate ester
- rofleponide triamcinolone acetonide
- ciclesonide butixocort propionate
- RPR-106541 the 17-propionate ester or the 17,21-dipropionate ester
- ST-126 the 17-propionate ester or the 17,21-dipropionate ester
- flunisolide e.g. the furoate ester
- triamcinolone acetonide e.g. the furoate ester
- rofleponide triamcinolone acetonide
- ciclesonide butixocort propionate
- Preferred corticosteroids include fluticasone propionate, 6 ⁇ ,9 ⁇ -difluoro-11 ⁇ -hydroxy-16 ⁇ -methyl-17 ⁇ -[(4-methyl- 1 ,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S- fluoromethyl ester and 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ - methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester, more preferably 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo- androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester.
- Suitable NSAIDs include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (e.g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists . and adenosine receptor agonists or antagonists (e.g. adenosine 2a agonists), cytokine antagonists (e.g. chemokine antagonists) or inhibitors of cytokine synthesis.
- PDE phosphodiesterase
- Suitable other ⁇ 2 -adrenoreceptor agonists include salmeterol (e.g. as the xinafoate), salbutamol (e.g. as the sulphate or the free base), formoterol (e.g. as the fumarate), fenoterol or terbutaline and salts thereof.
- salmeterol e.g. as the xinafoate
- salbutamol e.g. as the sulphate or the free base
- formoterol e.g. as the fumarate
- fenoterol or terbutaline e.g. as the fumarate
- the PDE4- specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family as well as PDE4.
- a PDE4 inhibitor which has an IC50 ratio of about 0.1 or greater as regards the IC50 for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC50 for the form which binds rolipram with a low affinity.
- the cAMP catalytic site which binds R and S rolipram with a low affinity is denominated the "low affinity” binding site (LPDE 4) and the other form of this catalytic site which binds rolipram with a high affinity is denominated the "high affinity” binding site (HPDE 4).
- LPDE 4 low affinity binding site
- HPDE 4 high affinity binding site
- PDE4 inhibitors of use in this invention will be those compounds which have a salutary therapeutic ratio, i.e., compounds which preferentially inhibit cAMP catalytic activity where the enzyme is in the form that binds rolipram with a low affinity, thereby reducing the side effects which apparently are linked to inhibiting the form which binds rolipram with a high affinity.
- the preferred compounds will have an IC5 0 ratio of about 0.1 or greater as regards the IC50 for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC50 for the form which binds rolipram with a low affinity.
- a further refinement of this standard is that of one wherein the PDE4 inhibitor has an IC50 ratio of about 0.1 or greater; said ratio is the ratio of the IC50 value for competing with the binding of 1nM of [ ⁇ HjR-rolipram to a form of PDE4 which binds rolipram with a high affinity over the IC50 value for inhibiting the PDE4 catalytic activity of a form which binds rolipram with a low affinity using 1 ⁇ M[3H]-cAMP as the substrate.
- PDE4 inhibitors which have an IC50 ratio of greater than 0.5, and particularly those compounds having a ratio of greater than 1.0.
- Preferred compounds are cis 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1- carboxylic acid, 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-1-one and c/s-[4-cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-1-ol]; these are examples of compounds which bind preferentially to the low affinity binding site and which have an IC50 ratio of 0.1 or greater.
- AWD-12-281 from elbion (Hofgen, N. etal. 15th EFMC Int Symp Med Chem (Sept 6-10, Edinburgh) 1998, Abst P.98; CAS reference No. 247584020-9); a 9-benzyladenine derivative nominated NCS-613 (INSERM); D-4418 from Chiroscience and Schering- Plough; a benzodiazepine PDE4 inhibitor identified as CI-1018 (PD-168787) and attributed to Pfizer; a benzodioxole derivative disclosed by Kyowa Hakko in WO99/16766; K-34 from Kyowa Hakko; V-11294A from Napp (Landells, L.J. et al.
- PDE-4 and mixed PDE3/PDE4 inhibitors include those listed in WO01/13953, the disclosure of which is hereby incorporated by reference.
- Suitable anticholinergic agents are those compounds that act as antagonists at the muscarinic receptor, in particular those compounds which are antagonists of the M ⁇ and M 2 receptors.
- Exemplary compounds include the alkaloids of the belladonna plants as illustrated by the likes of atropine, scopolamine, homatropine, hyoscyamine; these compounds are normally administered as a salt, being tertiary amines.
- These drugs, particularly the salt forms are readily available from a number of commercial sources or can be made or prepared from literature data via, to wit:
- Atropine - CAS-51-55-8 or CAS-51-48-1 (anhydrous form), atropine sulfate - CAS-5908- 99-6; atropine oxide - CAS-4438-22-6 or its HCl salt - CAS-4574-60-1 and methylatropine nitrate - CAS-52-88-0.
- Preferred anticholinergics include ipratropium (e.g. as the bromide), sold under the name Atrovent, oxitropium (e.g. as the bromide) and tiotropium (e.g. as the bromide) (CAS- 139404-48-1).
- methantheline (CAS-53-46-3), propantheline bromide (CAS- 50-34-9), anisotropine methyl bromide or Valpin 50 (CAS- 80-50-2), clidinium bromide (Quarzan, CAS-3485-62-9), copyrrolate (Robinul), isopropamide iodide (CAS-71- 81-8), mepenzolate bromide (U.S. patent 2,918,408), tridihexethyl chloride (Pathilone, CAS-4310-35-4), and hexocyclium methylsulfate (Tral, CAS-115-63-9).
- Suitable antihistamines include any one or more of the numerous antagonists known which inhibit Hi-receptors, and are safe for human use. All are reversible, competitive inhibitors of the interaction of histamine with Hi-receptors. The majority of these inhibitors, mostly first generation antagonists, have a core structure, which can be represented by the following formula:
- This generalized structure represents three types of antihistamines generally available: ethanolamines, ethylenediamines, and alkylamines.
- first generation antihistamines include those which can be characterized as based on piperizine and phenothiazines.
- Second generation antagonists which are non-sedating, have a similar structure-activity relationship in that they retain the core ethylene group (the alkylamines) or mimic the tertiary amine group with piperizine or piperidine.
- Exemplary antagonists are as follows:
- Ethanolamines carbinoxamine maleate, clemastine fumarate, diphenylhydramine hydrochloride, and dimenhydrinate.
- Ethylenediamines pyrilamine amleate, tripelennamine HCl, and tripelennamine citrate.
- Alkylamines chlropheniramine and its salts such as the maleate salt, and acrivastine.
- Piperazines hydroxyzine HCl, hydroxyzine pamoate, cyclizine HCl, cyclizine lactate, meclizine HCl, and cetirizine HCl.
- Piperidines Astemizole, levocabastine HCl, loratadine or its descarboethoxy analogue, and terfenadine and fexofenadine hydrochloride or another pharmaceutically acceptable salt.
- Azelastine hydrochloride is yet another Hi receptor antagonist which may be used in combination with a PDE4 inhibitor.
- Examples of preferred anti-histamines include methapyrilene and loratadine.
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a PDE4 inhibitor.
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a corticosteroid.
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with an anticholinergic.
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with an antihistamine.
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a PDE4 inhibitor and a corticosteroid.
- the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with an anticholinergic and a PDE-4 inhibitor.
- compositions comprising a combination as defined above together with a physiologically acceptable diluent or carrier represent a further aspect of the invention.
- the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
- a process for preparing a compound of formula (I) or a salt, solvate, or physiologically functional derivative thereof which comprises a process as defined below followed by the following steps in any order: (i) optional removal of any protecting groups;
- a compound of formula (I) may be obtained by deprotection of a protected intermediate, for example of formula (II):
- R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 and R 7 , m, and n are as defined for the compound of formula (I)
- Ar 1a represents an optionally protected form of Ar 1
- P 1 and P 2 are each independently either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group.
- Protected forms Ar 1a of the preferred groups Ar 1 may be selected from:
- Suitable protecting groups may be any conventional protecting group such as those described in "Protective Groups in Organic Synthesis” by Theodora W Greene and Peter G M Wuts, 3rd edition (John Wiley & Sons, 1999).
- suitable hydroxyl protecting groups represented by P 3 and P 4 are esters such as acetate ester, aralkyl groups such as benzyl, diphenylmethyl, or triphenylmethyl, and tetrahydropyranyl.
- Suitable amino protecting groups represented by P 2 include benzyl, ⁇ - methylbenzyl, diphenylmethyl, triphenylmethyl, benzyloxycarbonyl, tert-butoxycarbonyl, and acyl groups such as trichloroacetyl or trifluoroacetyl.
- protecting groups may include orthogonal protection of groups in the compounds of formula (II) to facilitate the selective removal of one group in the presence of another, thus enabling selective functionalisation of a single amino or hydroxyl function.
- the -CH(OH) group may be orthogonally protected as -CHOP 1 using, for example, a trialkylsilyl group such as triethylsilyl.
- a trialkylsilyl group such as triethylsilyl.
- orthogonal protection strategies available by conventional means as described in Theodora W Greene (see above).
- the deprotection to yield a compound of formula (I) may be effected using conventional techniques.
- P 3 , P 4 , and/or P 2 is an aralkyl group
- this may be cleaved by hydrogenolysis in the presence of a metal catalyst (e.g. palladium on charcoal).
- a metal catalyst e.g. palladium on charcoal
- P 3 and/or P 4 When P 3 and/or P 4 is tetrahydropyranyl this may be cleaved by hydrolysis under acidic conditions.
- Acyl groups represented by P 2 may be removed by hydrolysis, for example with a base such as sodium hydroxide, or a group such as trichloroethoxycarbonyl may be removed by reduction with, for example, zinc and acetic acid. Other deprotection methods may be found in Theodora W Greene (see above).
- P 3 and P 4 may together represent a protecting group as in the compound of formula (III).
- R 23 and R 24 are independently selected from hydrogen,
- a compound of formula (III) may be converted to a compound of formula (I) by hydrolysis with dilute aqueous acid, for example acetic acid or hydrochloric acid in a suitable solvent or by transketalisation in an alcohol, for example ethanol, in the presence of a catalyst such as an acid (for example, toluenesulphonic acid) or a salt (such as pyridinium tosylate) at normal or elevated temperature.
- a catalyst such as an acid (for example, toluenesulphonic acid) or a salt (such as pyridinium tosylate) at normal or elevated temperature.
- protecting groups P 1 , P 2 , P 3 and P 4 may be removed in a single step or sequentially.
- the precise order in which protecting groups are removed will in part depend upon the nature of said groups and will be readily apparent to the skilled worker.
- this protecting group is removed together with any protecting group on the CH(OH) moiety, followed by removal of P 2 .
- a compound of formula (IV) to a compound of formula (II) or (III) may be effected by treatment with a base, for example a non-aqueous base, such as potassium trimethylsilanolate, or an aqueous base such as aqueous sodium hydroxide, in a suitable solvent such as tetrahydrofuran.
- a base for example a non-aqueous base, such as potassium trimethylsilanolate, or an aqueous base such as aqueous sodium hydroxide, in a suitable solvent such as tetrahydrofuran.
- R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , m and n are as defined for the compound of formula (IV) and L 1 is a leaving group, for example a halo group (typically bromo or iodo) or a sulfonate such as an alkyl sulfonate (typically, methanesulfonate), an arylsulfonate (typically, toluenesulfonate), or a haloalkyl sulfonate (typically, trifluoromethanesulfonate).
- a halo group typically bromo or iodo
- a sulfonate such as an alkyl sulfonate (typically, methanesulfonate), an arylsulfonate (typically, toluenesulfonate), or a haloalkyl sulfonate (
- the coupling of a compound of formula (V) with a compound of formula (VI) may be effected in the presence of a base, such as a metal hydride, for example sodium hydride, or an inorganic base such as cesium carbonate, in an aprotic solvent, for example N,N- dimethylformamide or tetrahydrofuran.
- a base such as a metal hydride, for example sodium hydride, or an inorganic base such as cesium carbonate
- an aprotic solvent for example N,N- dimethylformamide or tetrahydrofuran.
- R 4 , R 5 and m are as defined for compounds of formula (I) and each L 1 which may be the same or different represents a leaving group, eg. as defined above for compounds of formula (VI);
- R° wherein R ⁇ R 2 , R 3 , R 6 , R 7 and n are as defined for compounds of formula (VI).
- the coupling of compounds (VII) and (VIII) may be effected in the presence of an inorganic base, such as aqueous sodium hydroxide, under phase transfer conditions in the presence of an ammonium salt such as tetraalkylammonium bromide.
- an inorganic base such as aqueous sodium hydroxide
- an ammonium salt such as tetraalkylammonium bromide.
- a compound of formula (IV) may be prepared by reacting a compound of formula (IX):
- the coupling of a compound of formula (IX) with a compound of formula (VIII) may be effected in the presence of a base, such as metal hydride, for example sodium hydride, an alkoxide such as potassium t-butoxide or an inorganic base such as caesium carbonate, in an aprotic solvent, for example dimethylformamide.
- a base such as metal hydride, for example sodium hydride, an alkoxide such as potassium t-butoxide or an inorganic base such as caesium carbonate
- a compound of formula (IX) may be prepared by coupling a compound of formula (V) as hereinbefore defined with a compound of formula (VII) as hereinbefore defined, using a method analogous to the coupling of a compound of formula (IX) with a compound of formula (VIII), as described hereinabove.
- a compound of formula (I) may be obtained by alkylation of an amine of formula (X):
- P 1 and P 2 are each independently either hydrogen or a protecting group and Ar 1a is as hereinbefore defined. Suitable protecting groups are discussed in the definition of compounds of formula (II);
- reaction of compounds of formulae (X) and (VI) is optionally effected in the presence of an organic base such as a trialkylamine, for example, diisopropylethylamine, and in a suitable solvent for example dimethyl formamide.
- organic base such as a trialkylamine, for example, diisopropylethylamine, and in a suitable solvent for example dimethyl formamide.
- the enantiomeric compounds of the invention may be obtained (i) by separation of the components of the corresponding racemic mixture, for example, by means of a chiral chromatography column, enzymic resolution methods, or preparing and separating suitable diastereoisomers, or (ii) by direct synthesis from the appropriate chiral intermediates by the methods described above.
- Optional conversions of a compound of formula (I) to a corresponding salt may conveniently be effected by reaction with the appropriate acid or base.
- Optional conversion of a compound of formula (I) to a corresponding solvate or physiologically functional derivative may be effected by methods known to those skilled in the art.
- KOSiMe 3 potassium trimethylsilanolate bp : boiling point ca : circa h : hour(s) min : minute(s)
- Silica gel refers to Merck silica gel 60 Art number 7734.
- Flash silica gel refers to Merck silica gel 60 Art number 9385.
- Biotage refers to prepacked silica gel cartridges containing KP-Sil run on flash 12i chromatography module.
- Bond Elut are prepacked cartridges used in parallel purifications, normally under vacuum. These are commercially available from Varian. NMR experiments at 400MHz (unless specified otherwise).
- LCMS was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm x 4.6 mm ID) eluting with 0.1% HCO 2 H and 0.01 M ammonium acetate in water (solvent A), and 0.05% HCO 2 H 5% water in acetonitrile (solvent B), using the following elution gradient 0-0.7 min 0%B, 0.7-4.2 min 100%B, 4.2-5.3 min 0%B, 5.3-5.5 min 0%B at a flow rate of 3 ml/min.
- the mass spectra were recorded on a Fisons VG Platform spectrometer using electrospray positive and negative mode (ES+ve and ES-ve).
- BIOLOGICAL ACTIVITY In vitro measurements of compound potency and intrinsic activitv at the human Beta 1. 2 and 3 receptors.
- the potencies of the compounds of Examples 1 and 2 were determined using frog melanophores transfected with the human beta 2 adrenoreceptor. The cells were incubated with melatonin to induce pigment aggregation. Pigment dispersal was induced by compounds acting on the human beta 2 adrenoreceptor. The beta 2 agonist activity of test compounds was assessed by their ability to induce a change in light transmittance across a melanophore monolayer (a consequence of pigment dispersal). At the human beta 2 adrenoreceptor, compounds of said examples had IC 50 values below 1 ⁇ M.
- Potency of compounds of the invention at the human beta 2, 1 and 3 receptors was also determined using Chinese hamster ovary cells co-expressing the human receptor with a reporter gene. Studies were performed using either whole cells or membranes derived from those cells.
- the three beta-receptors are coupled via the Gs G-protein to cause a stimulation of adenylate cyclase resulting in increased levels of cAMP in the cell.
- adenylate cyclase resulting in increased levels of cAMP in the cell.
- membranes or cells have been used with either the HitHunter enzyme fragment complementation kit (DiscoveRx) or the FP 2 fluorescence polarisation kit (Perkin Elmer) to quantify the levels of cAMP present.
- HitHunter enzyme fragment complementation kit DiscoveRx
- FP 2 fluorescence polarisation kit Perkin Elmer
- the reporter gene in the cells has also been used to quantify potency at the beta 1 and 3 receptors. This is a reporter of cAMP levels using the cAMP response element upstream of a firefly luciferase gene. After stimulation of the receptor with an agonist an increase in the level of luciferase is measured as a quantification of the level of cAMP in the cell.
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003293632A AU2003293632A1 (en) | 2002-10-28 | 2003-10-24 | Phenethanolamine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0225030.6 | 2002-10-28 | ||
GBGB0225030.6A GB0225030D0 (en) | 2002-10-28 | 2002-10-28 | Medicinal compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004037768A2 true WO2004037768A2 (fr) | 2004-05-06 |
WO2004037768A3 WO2004037768A3 (fr) | 2004-07-29 |
Family
ID=9946704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/012038 WO2004037768A2 (fr) | 2002-10-28 | 2003-10-24 | Composes a usage medicinal |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003293632A1 (fr) |
GB (1) | GB0225030D0 (fr) |
WO (1) | WO2004037768A2 (fr) |
Cited By (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005452A1 (fr) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Compose glucocorticosteroide specifique a activite anti-inflammatoire |
WO2005116037A1 (fr) | 2004-05-24 | 2005-12-08 | Glaxo Group Limited | Dérivé de purine |
WO2006015870A1 (fr) | 2004-08-12 | 2006-02-16 | Glaxo Group Limited | Dérivés de tétrahydronaphthalène servant de modulateurs du récepteur des glucocorticoïdes |
WO2006056471A1 (fr) | 2004-11-29 | 2006-06-01 | Novartis Ag | Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2 |
WO2006108643A2 (fr) | 2005-04-14 | 2006-10-19 | Novartis Ag | Composes organiques |
WO2007009757A1 (fr) | 2005-07-19 | 2007-01-25 | Glaxo Group Limited | Derives de purine agonistes du recepteur de l'adenosine a2a |
WO2007122165A1 (fr) | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Nouveaux composés |
WO2007121920A2 (fr) | 2006-04-21 | 2007-11-01 | Novartis Ag | Composés organiques |
WO2007144327A2 (fr) | 2006-06-12 | 2007-12-21 | Glaxo Group Limited | Nouveaux composés |
WO2007150016A2 (fr) | 2006-06-23 | 2007-12-27 | Smithkline Beecham Corporation | Antagoniste du récepteur il-8 |
WO2008015416A1 (fr) | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Composés de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4 |
US7402673B2 (en) | 2004-06-03 | 2008-07-22 | Theravance, Inc. | Diamine β2 adrenergic receptor agonists |
WO2008118724A1 (fr) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides en tant qu'inhibiteurs d'ikk2 |
WO2009087224A1 (fr) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines utilisés en tant qu'inhibiteurs de kinase |
US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
WO2009147187A1 (fr) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases |
WO2009150137A2 (fr) | 2008-06-10 | 2009-12-17 | Novartis Ag | Composés organiques |
EP2157087A1 (fr) | 2005-12-20 | 2010-02-24 | Glaxo Group Limited | Acide 3-(4-{[4-(4-{[3-(3,3-diméthyl-1-pipéridinyl)propyl]oxy}phényl)-1-pipéridinyl]carbonyl}-1-naphthalenyl)propanoïque ou propenoïque comme antagonistes des récepteurs h1 et h3 pour le traitement de maladies inflammatoires et/ou allergiques |
WO2010068311A1 (fr) | 2008-05-23 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Inhibiteur de la protéine d’activation de 5-lipoxygénase |
EP2206499A1 (fr) | 2004-11-02 | 2010-07-14 | Novartis AG | Derives de quinuclidine et leur utilisation en tant qu'antagonistes des recépteurs muscariniques m3 |
WO2010094643A1 (fr) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Dérivés de quinoline et applications associées dans la rhinite et l'urticaire |
WO2010102968A1 (fr) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Dérivés d'indole comme inhibiteurs de ikk2 |
WO2010102958A1 (fr) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases |
WO2010107952A2 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par arn interférence de l'expression génique de facteur de croissance de tissu conjonctif (ctgf) en utilisant un acide nucléique interférant court (ansi) |
WO2010107957A2 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Inhibition induite par arn interférence d'une expression génique (gata3) d'une protéine de liaison gata au moyen d'un acide nucléique interférent court |
WO2010106016A1 (fr) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Dérivés de pyrimidine utilisés comme inhibiteurs de ltk |
WO2010107958A1 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | INHIBITION INDUITE PAR ARN INTERFÉRENCE DE L'EXPRESSION DU GÈNE TRANSDUCTEUR DE SIGNAL ET ACTIVITATEUR DE TRANSCRIPTION 6 (STAT6) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANsi) |
WO2010107955A2 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par arn interférence de l'expression génique de btb et de l'homologie cnc 1, facteur de transcription 1 de fermeture éclair de leucine basique (bach 1), utilisant une liste de séquences d'acide nucléique interférant court (ansi) |
WO2010111490A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition à médiation par l'interférence arn de l'expression du gène de la lymphopoïétine stromale thymique (tslp) faisant appel à de courts acides nucléiques interférents (ansi) |
WO2010111497A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition à médiation par l'interférence arn de l'expression du gène de la molécule d'adhésion intercellulaire 1 (icam-1) faisant appel à de courts acides nucléiques interférents (ansi) |
WO2010111471A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène du signal transducteur et activateur de la transcription 1 (stat1) au moyen d'un acide nucléique interférent court (ansi) |
WO2010111468A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI) |
WO2010111464A1 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi) |
WO2010122089A1 (fr) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Carboxamides n-pyrazolyl en tant qu'inhibiteurs du canal crac |
WO2010122088A1 (fr) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole et triazole carboxamides en tant qu'inhibiteurs du canal crac |
WO2010150014A1 (fr) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires |
EP2280006A1 (fr) | 2005-08-08 | 2011-02-02 | Pulmagen Therapeutics (Synergy) Limited | Composition pharmaceutique pour inhalation comprenant un oxazole ou thiazole antagoniste du récepteur m3 muscarinique |
EP2279777A2 (fr) | 2007-01-10 | 2011-02-02 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de protéase à activation de canal |
EP2281813A1 (fr) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Dérivés de bicyclo[2.2.1]hept-7-ylamine et leurs utilisations |
EP2281819A1 (fr) | 2004-01-21 | 2011-02-09 | Novartis AG | Dérivés du benzimidazole ou du benzoxazole |
EP2286813A2 (fr) | 2006-01-31 | 2011-02-23 | Novartis AG | Utilisation de dérivés de naphthyridine comme medicaments |
EP2292619A1 (fr) | 2004-10-22 | 2011-03-09 | Novartis AG | Derivés de purin et leurs utilisation comme agonists d'adenosin-A2A-récepteur |
WO2011050325A1 (fr) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques |
WO2011051673A1 (fr) | 2009-10-28 | 2011-05-05 | Vantia Limited | Dérivés aminothiazole utiles comme inhibiteurs de la klk1 |
WO2011051672A1 (fr) | 2009-10-28 | 2011-05-05 | Vantia Limited | Dérivés azaindole |
WO2011051671A1 (fr) | 2009-10-28 | 2011-05-05 | Vantia Limited | Dérivés aminopyridine comme inhibiteurs de la kallicréine |
WO2011067366A1 (fr) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Dérivés d'indazole comme inhibiteurs des pi3-kinases |
WO2011067365A1 (fr) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases |
WO2011067364A1 (fr) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Nouveaux composés |
EP2332933A1 (fr) | 2007-05-07 | 2011-06-15 | Novartis AG | Inhibiteurs du canal sodique épithélial |
WO2011084316A2 (fr) | 2009-12-16 | 2011-07-14 | 3M Innovative Properties Company | Formulations et procédés pour le réglage de l'administration de particules d'une certaine taille dans un aérosol-doseur |
WO2011098799A2 (fr) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Traitement de maladie respiratoire |
WO2011098746A1 (fr) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone |
WO2011098801A1 (fr) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Traitement de maladies inflammatoires |
WO2011110575A1 (fr) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires |
WO2011113894A1 (fr) | 2010-03-19 | 2011-09-22 | Novartis Ag | Dérivés de pyridine et de pyrazine pour le traitement de la mucoviscidose |
WO2011134971A1 (fr) | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | Composés de 7-(1h-pyrazol-4-yl)-1,6-naphtyridine comme inhibiteurs de syk |
WO2012034091A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions à titre d'inhibiteurs de trk |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
WO2012032067A1 (fr) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphes et sels de n-[5-[4-(5-{[(2r,6s-2,6-diméthyl-4-morpholinyl]- méthyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(méthyloxy)-3-pyridinyl]- méthanesulfonamide |
WO2012035055A1 (fr) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Nouveaux composés |
WO2012035158A1 (fr) | 2010-09-17 | 2012-03-22 | Novartis Ag | Dérivés de la pyrazine en tant que bloqueurs de l'enac |
EP2436686A1 (fr) | 2005-03-25 | 2012-04-04 | Glaxo Group Limited | Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38 |
EP2444120A1 (fr) | 2007-12-10 | 2012-04-25 | Novartis AG | Analogues d'Amiloride spirocyclique en tant que blocker d'ENaC |
WO2012052458A1 (fr) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Composés pyrazole agissant contre des états allergiques, immunitaires et inflammatoires |
WO2012052459A1 (fr) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Composés de pyrazole agissant contre des troubles allergiques, inflammatoires et immunitaires |
WO2012055846A1 (fr) | 2010-10-27 | 2012-05-03 | Glaxo Group Limited | Polymorphes et sels de 6-(1h-indol-4-yl)-4-(5-{[4-(1-méthyléthyl)-1-pipérazinyl]méthyl}-1,3-oxazol-2-yl)-1h-indazole comme inhibiteurs de pi3k destinés à être utilisés dans le traitement par exemple de troubles respiratoires |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2012116217A1 (fr) | 2011-02-25 | 2012-08-30 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de trk |
WO2012123312A1 (fr) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk |
WO2012123311A1 (fr) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Dérivés pyrdinyl- et pyrazinyl-méthyloxy-aryle utiles en tant qu'inhibiteurs de la tyrosine kinase de la rate (syk) |
EP2532677A1 (fr) | 2005-10-21 | 2012-12-12 | Novartis AG | Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques |
US8337816B2 (en) | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
US8362064B2 (en) | 2008-12-30 | 2013-01-29 | Pulmagen Theraputics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2013030802A1 (fr) | 2011-09-01 | 2013-03-07 | Novartis Ag | Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire |
WO2013038378A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyridinamides |
WO2013038381A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés d'amide pyridine/pyrazine |
WO2013038386A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Composés hétérocycliques destinés au traitement de la mucosviscidose |
WO2013038373A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyrimidinamides |
WO2013038390A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Hétérocyclyle carboxamides n-substitués |
WO2013140319A1 (fr) | 2012-03-19 | 2013-09-26 | Novartis Ag | Forme cristalline d'un sel de succinate |
WO2014132220A1 (fr) | 2013-03-01 | 2014-09-04 | Novartis Ag | Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf |
WO2015055691A1 (fr) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Inhibiteur de pi3k pour le traitement d'une maladie respiratoire |
WO2015055690A1 (fr) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Inhibiteur de pi3k pour le traitement d'une maladie respiratoire |
EP2899191A1 (fr) | 2009-04-30 | 2015-07-29 | Glaxo Group Limited | Nouveaux composés |
WO2015162461A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
WO2015162456A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
WO2015162459A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
WO2015173701A2 (fr) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compositions pharmaceutiques pour traiter des maladies infecteuses |
WO2017137535A1 (fr) | 2016-02-12 | 2017-08-17 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques comme inhibiteurs de l'activité kinase |
WO2018029126A1 (fr) | 2016-08-08 | 2018-02-15 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
WO2018192864A1 (fr) | 2017-04-18 | 2018-10-25 | Glaxosmithkline Intellectual Property Development Limited | Dérivés d'oxépinopyrazole en tant qu'inhibiteurs de l'activité de kinase pi3 |
WO2019020657A1 (fr) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Composés de pyridine-3-sulfonamide utilisés en tant qu'inhibiteurs de pi3-kinase |
WO2020250116A1 (fr) | 2019-06-10 | 2020-12-17 | Novartis Ag | Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie |
WO2021038426A1 (fr) | 2019-08-28 | 2021-03-04 | Novartis Ag | Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2140800A (en) * | 1983-04-18 | 1984-12-05 | Glaxo Group Ltd | Phenethanolamine derivatives |
GB2230525A (en) * | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(Hydroxyphenyl)-2-aminoethanol derivatives |
WO1995019336A1 (fr) * | 1994-01-12 | 1995-07-20 | Iovis Biomedical And Pharmaceutical Consultants | Ethers de phenylethanolamine et leur utilisation comme agonistes des recepteurs adrenergiques beta |
-
2002
- 2002-10-28 GB GBGB0225030.6A patent/GB0225030D0/en not_active Ceased
-
2003
- 2003-10-24 WO PCT/EP2003/012038 patent/WO2004037768A2/fr not_active Application Discontinuation
- 2003-10-24 AU AU2003293632A patent/AU2003293632A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2140800A (en) * | 1983-04-18 | 1984-12-05 | Glaxo Group Ltd | Phenethanolamine derivatives |
GB2230525A (en) * | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(Hydroxyphenyl)-2-aminoethanol derivatives |
WO1995019336A1 (fr) * | 1994-01-12 | 1995-07-20 | Iovis Biomedical And Pharmaceutical Consultants | Ethers de phenylethanolamine et leur utilisation comme agonistes des recepteurs adrenergiques beta |
Cited By (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8337816B2 (en) | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
US7291609B2 (en) | 2003-07-11 | 2007-11-06 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti-inflammatory activity |
WO2005005451A1 (fr) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Compose de glucocorticosteroide specifique presentant une active anti-inflammatoire |
EP2380898A1 (fr) | 2003-07-11 | 2011-10-26 | Glaxo Group Limited | Procédé de fabrication de composés glucocortisoides |
WO2005005452A1 (fr) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Compose glucocorticosteroide specifique a activite anti-inflammatoire |
US7288536B2 (en) | 2003-07-11 | 2007-10-30 | Glaxo Group Limited | Specific glucocorticosteroid compound having anti-inflammatory activity |
US7638508B2 (en) | 2003-07-11 | 2009-12-29 | Glaxo Group Limited | Glucocorticosteroid compound having anti-inflammatory activity |
EP2281819A1 (fr) | 2004-01-21 | 2011-02-09 | Novartis AG | Dérivés du benzimidazole ou du benzoxazole |
WO2005116037A1 (fr) | 2004-05-24 | 2005-12-08 | Glaxo Group Limited | Dérivé de purine |
US7402673B2 (en) | 2004-06-03 | 2008-07-22 | Theravance, Inc. | Diamine β2 adrenergic receptor agonists |
US7902224B2 (en) | 2004-08-12 | 2011-03-08 | Glaxo Group Limited | Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators |
WO2006015870A1 (fr) | 2004-08-12 | 2006-02-16 | Glaxo Group Limited | Dérivés de tétrahydronaphthalène servant de modulateurs du récepteur des glucocorticoïdes |
EP2292619A1 (fr) | 2004-10-22 | 2011-03-09 | Novartis AG | Derivés de purin et leurs utilisation comme agonists d'adenosin-A2A-récepteur |
EP2206499A1 (fr) | 2004-11-02 | 2010-07-14 | Novartis AG | Derives de quinuclidine et leur utilisation en tant qu'antagonistes des recépteurs muscariniques m3 |
EP2305659A1 (fr) | 2004-11-29 | 2011-04-06 | Novartis AG | Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2 |
WO2006056471A1 (fr) | 2004-11-29 | 2006-06-01 | Novartis Ag | Derives de 5-hydroxy-benzothiazole presentant une activite agoniste de l'adrenorecepteur beta-2 |
US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
EP2436686A1 (fr) | 2005-03-25 | 2012-04-04 | Glaxo Group Limited | Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38 |
EP2447266A1 (fr) | 2005-03-25 | 2012-05-02 | Glaxo Group Limited | Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38 |
WO2006108643A2 (fr) | 2005-04-14 | 2006-10-19 | Novartis Ag | Composes organiques |
EP2253612A1 (fr) | 2005-04-14 | 2010-11-24 | Novartis AG | Composés organiques |
WO2007009757A1 (fr) | 2005-07-19 | 2007-01-25 | Glaxo Group Limited | Derives de purine agonistes du recepteur de l'adenosine a2a |
EP2281813A1 (fr) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Dérivés de bicyclo[2.2.1]hept-7-ylamine et leurs utilisations |
EP2280006A1 (fr) | 2005-08-08 | 2011-02-02 | Pulmagen Therapeutics (Synergy) Limited | Composition pharmaceutique pour inhalation comprenant un oxazole ou thiazole antagoniste du récepteur m3 muscarinique |
EP2532679A1 (fr) | 2005-10-21 | 2012-12-12 | Novartis AG | Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques |
EP2532677A1 (fr) | 2005-10-21 | 2012-12-12 | Novartis AG | Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques |
EP2157087A1 (fr) | 2005-12-20 | 2010-02-24 | Glaxo Group Limited | Acide 3-(4-{[4-(4-{[3-(3,3-diméthyl-1-pipéridinyl)propyl]oxy}phényl)-1-pipéridinyl]carbonyl}-1-naphthalenyl)propanoïque ou propenoïque comme antagonistes des récepteurs h1 et h3 pour le traitement de maladies inflammatoires et/ou allergiques |
EP2286813A2 (fr) | 2006-01-31 | 2011-02-23 | Novartis AG | Utilisation de dérivés de naphthyridine comme medicaments |
WO2007122165A1 (fr) | 2006-04-20 | 2007-11-01 | Glaxo Group Limited | Nouveaux composés |
EP2322525A1 (fr) | 2006-04-21 | 2011-05-18 | Novartis AG | Derives de purine comme d'agonistes des recepteurs de l'adenosine A2A |
WO2007121920A2 (fr) | 2006-04-21 | 2007-11-01 | Novartis Ag | Composés organiques |
WO2007144327A2 (fr) | 2006-06-12 | 2007-12-21 | Glaxo Group Limited | Nouveaux composés |
WO2007150016A2 (fr) | 2006-06-23 | 2007-12-27 | Smithkline Beecham Corporation | Antagoniste du récepteur il-8 |
WO2008015416A1 (fr) | 2006-08-01 | 2008-02-07 | Glaxo Group Limited | Composés de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4 |
EP2279777A2 (fr) | 2007-01-10 | 2011-02-02 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de protéase à activation de canal |
WO2008118724A1 (fr) | 2007-03-23 | 2008-10-02 | Smithkline Beecham Corporation | Indole carboxamides en tant qu'inhibiteurs d'ikk2 |
EP2332933A1 (fr) | 2007-05-07 | 2011-06-15 | Novartis AG | Inhibiteurs du canal sodique épithélial |
EP2520574A1 (fr) | 2007-12-10 | 2012-11-07 | Novartis AG | Analogues d'Amiloride substitués sur la partie cyclique de la guanidine en tant que bloqueurs d'ENaC pour le traitement de maladies respiratoires |
EP2444120A1 (fr) | 2007-12-10 | 2012-04-25 | Novartis AG | Analogues d'Amiloride spirocyclique en tant que blocker d'ENaC |
WO2009087224A1 (fr) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines utilisés en tant qu'inhibiteurs de kinase |
WO2010068311A1 (fr) | 2008-05-23 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Inhibiteur de la protéine d’activation de 5-lipoxygénase |
WO2009147187A1 (fr) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases |
WO2009150137A2 (fr) | 2008-06-10 | 2009-12-17 | Novartis Ag | Composés organiques |
US8815837B2 (en) | 2008-08-07 | 2014-08-26 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US9078885B2 (en) | 2008-08-07 | 2015-07-14 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
US8362064B2 (en) | 2008-12-30 | 2013-01-29 | Pulmagen Theraputics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010094643A1 (fr) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Dérivés de quinoline et applications associées dans la rhinite et l'urticaire |
WO2010102958A1 (fr) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases |
WO2010102968A1 (fr) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Dérivés d'indole comme inhibiteurs de ikk2 |
WO2010106016A1 (fr) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Dérivés de pyrimidine utilisés comme inhibiteurs de ltk |
WO2010107952A2 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par arn interférence de l'expression génique de facteur de croissance de tissu conjonctif (ctgf) en utilisant un acide nucléique interférant court (ansi) |
WO2010107957A2 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Inhibition induite par arn interférence d'une expression génique (gata3) d'une protéine de liaison gata au moyen d'un acide nucléique interférent court |
WO2010107958A1 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | INHIBITION INDUITE PAR ARN INTERFÉRENCE DE L'EXPRESSION DU GÈNE TRANSDUCTEUR DE SIGNAL ET ACTIVITATEUR DE TRANSCRIPTION 6 (STAT6) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANsi) |
WO2010107955A2 (fr) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | Inhibition médiée par arn interférence de l'expression génique de btb et de l'homologie cnc 1, facteur de transcription 1 de fermeture éclair de leucine basique (bach 1), utilisant une liste de séquences d'acide nucléique interférant court (ansi) |
WO2010111464A1 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi) |
WO2010111490A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition à médiation par l'interférence arn de l'expression du gène de la lymphopoïétine stromale thymique (tslp) faisant appel à de courts acides nucléiques interférents (ansi) |
WO2010111497A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition à médiation par l'interférence arn de l'expression du gène de la molécule d'adhésion intercellulaire 1 (icam-1) faisant appel à de courts acides nucléiques interférents (ansi) |
WO2010111471A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène du signal transducteur et activateur de la transcription 1 (stat1) au moyen d'un acide nucléique interférent court (ansi) |
WO2010111468A2 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI) |
WO2010122088A1 (fr) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole et triazole carboxamides en tant qu'inhibiteurs du canal crac |
WO2010122089A1 (fr) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Carboxamides n-pyrazolyl en tant qu'inhibiteurs du canal crac |
EP2899191A1 (fr) | 2009-04-30 | 2015-07-29 | Glaxo Group Limited | Nouveaux composés |
EP3260453A1 (fr) | 2009-04-30 | 2017-12-27 | Glaxo Group Limited | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase |
WO2010150014A1 (fr) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires |
WO2011050325A1 (fr) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions destinées au traitement de la mucoviscidose et d'autres maladies chroniques |
EP2813227A1 (fr) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions pour le traitement de la mucoviscidose et d'autres maladies chroniques |
WO2011051672A1 (fr) | 2009-10-28 | 2011-05-05 | Vantia Limited | Dérivés azaindole |
WO2011051673A1 (fr) | 2009-10-28 | 2011-05-05 | Vantia Limited | Dérivés aminothiazole utiles comme inhibiteurs de la klk1 |
WO2011051671A1 (fr) | 2009-10-28 | 2011-05-05 | Vantia Limited | Dérivés aminopyridine comme inhibiteurs de la kallicréine |
WO2011067364A1 (fr) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Nouveaux composés |
WO2011067366A1 (fr) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Dérivés d'indazole comme inhibiteurs des pi3-kinases |
WO2011067365A1 (fr) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases |
WO2011084316A2 (fr) | 2009-12-16 | 2011-07-14 | 3M Innovative Properties Company | Formulations et procédés pour le réglage de l'administration de particules d'une certaine taille dans un aérosol-doseur |
EP3020393A1 (fr) | 2009-12-16 | 2016-05-18 | 3M Innovative Properties Company of 3M Center | Formulations et procédés de commande de distribution granulométrique mdi |
WO2011098746A1 (fr) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone |
WO2011098799A2 (fr) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Traitement de maladie respiratoire |
WO2011098801A1 (fr) | 2010-02-10 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Traitement de maladies inflammatoires |
WO2011110575A1 (fr) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires |
US9365552B2 (en) | 2010-03-19 | 2016-06-14 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US11911371B2 (en) | 2010-03-19 | 2024-02-27 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of chronic bronchitis |
EP2845593A1 (fr) | 2010-03-19 | 2015-03-11 | Novartis AG | Dérivé de pyridine et de pyrazine pour le traitement d'une maladie pulmonaire obstructive chronique |
WO2011113894A1 (fr) | 2010-03-19 | 2011-09-22 | Novartis Ag | Dérivés de pyridine et de pyrazine pour le traitement de la mucoviscidose |
USRE46757E1 (en) | 2010-03-19 | 2018-03-20 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US10117858B2 (en) | 2010-03-19 | 2018-11-06 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
WO2011134971A1 (fr) | 2010-04-29 | 2011-11-03 | Glaxo Group Limited | Composés de 7-(1h-pyrazol-4-yl)-1,6-naphtyridine comme inhibiteurs de syk |
WO2012032067A1 (fr) | 2010-09-08 | 2012-03-15 | Glaxo Group Limited | Polymorphes et sels de n-[5-[4-(5-{[(2r,6s-2,6-diméthyl-4-morpholinyl]- méthyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(méthyloxy)-3-pyridinyl]- méthanesulfonamide |
WO2012034091A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions à titre d'inhibiteurs de trk |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
WO2012035055A1 (fr) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Nouveaux composés |
WO2012035158A1 (fr) | 2010-09-17 | 2012-03-22 | Novartis Ag | Dérivés de la pyrazine en tant que bloqueurs de l'enac |
WO2012052458A1 (fr) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Composés pyrazole agissant contre des états allergiques, immunitaires et inflammatoires |
WO2012052459A1 (fr) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Composés de pyrazole agissant contre des troubles allergiques, inflammatoires et immunitaires |
EP3447055A1 (fr) | 2010-10-27 | 2019-02-27 | Glaxo Group Limited | Combinations des polymorphes et sels de 6-(1h-indole-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole comme inhibituers de pi3k inhibitors pour leur utilisation dans le traitement des, par example, troubles respiratoires |
WO2012055846A1 (fr) | 2010-10-27 | 2012-05-03 | Glaxo Group Limited | Polymorphes et sels de 6-(1h-indol-4-yl)-4-(5-{[4-(1-méthyléthyl)-1-pipérazinyl]méthyl}-1,3-oxazol-2-yl)-1h-indazole comme inhibiteurs de pi3k destinés à être utilisés dans le traitement par exemple de troubles respiratoires |
WO2012116217A1 (fr) | 2011-02-25 | 2012-08-30 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de trk |
WO2012123311A1 (fr) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Dérivés pyrdinyl- et pyrazinyl-méthyloxy-aryle utiles en tant qu'inhibiteurs de la tyrosine kinase de la rate (syk) |
WO2012123312A1 (fr) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk |
EP2937344A1 (fr) | 2011-03-11 | 2015-10-28 | Glaxo Group Limited | Dérivés pyrdinyl- et pyrazinyl-méthyloxy-aryle utiles en tant qu'inhibiteurs de la tyrosine kinase de la rate (syk) |
WO2013030802A1 (fr) | 2011-09-01 | 2013-03-07 | Novartis Ag | Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire |
WO2013038386A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Composés hétérocycliques destinés au traitement de la mucosviscidose |
WO2013038390A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Hétérocyclyle carboxamides n-substitués |
WO2013038378A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyridinamides |
WO2013038381A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés d'amide pyridine/pyrazine |
WO2013038373A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Dérivés pyrimidinamides |
WO2013140319A1 (fr) | 2012-03-19 | 2013-09-26 | Novartis Ag | Forme cristalline d'un sel de succinate |
WO2014132220A1 (fr) | 2013-03-01 | 2014-09-04 | Novartis Ag | Formes solides de dérivés hétérocycliques bicycliques utilisées en tant que médiateurs du récepteur pdgf |
WO2015055690A1 (fr) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Inhibiteur de pi3k pour le traitement d'une maladie respiratoire |
WO2015055691A1 (fr) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Inhibiteur de pi3k pour le traitement d'une maladie respiratoire |
WO2015162456A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
WO2015162459A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
WO2015162461A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
WO2015173701A2 (fr) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compositions pharmaceutiques pour traiter des maladies infecteuses |
WO2017137535A1 (fr) | 2016-02-12 | 2017-08-17 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques comme inhibiteurs de l'activité kinase |
WO2018029126A1 (fr) | 2016-08-08 | 2018-02-15 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
WO2018192864A1 (fr) | 2017-04-18 | 2018-10-25 | Glaxosmithkline Intellectual Property Development Limited | Dérivés d'oxépinopyrazole en tant qu'inhibiteurs de l'activité de kinase pi3 |
WO2019020657A1 (fr) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Composés de pyridine-3-sulfonamide utilisés en tant qu'inhibiteurs de pi3-kinase |
WO2020250116A1 (fr) | 2019-06-10 | 2020-12-17 | Novartis Ag | Dérivé de pyridine et de pyrazine pour le traitement de la fk, de la bpco et de la bronchiectasie |
WO2021038426A1 (fr) | 2019-08-28 | 2021-03-04 | Novartis Ag | Dérivés de 1,3-phényl hétéroaryle substitués et leur utilisation dans le traitement d'une maladie |
Also Published As
Publication number | Publication date |
---|---|
AU2003293632A8 (en) | 2004-05-13 |
WO2004037768A3 (fr) | 2004-07-29 |
GB0225030D0 (en) | 2002-12-04 |
AU2003293632A1 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004037768A2 (fr) | Composes a usage medicinal | |
EP1370521B1 (fr) | Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2 | |
EP1675823B1 (fr) | Derives de phenethanolamine utilises dans le traitement de maladies respiratoires | |
EP1556342B1 (fr) | Derive de phenethanolamine utilise dans le traitement de maladies respiratoires | |
EP1554264B1 (fr) | Derives d'arylethanolamine a usage medicinal | |
US7538127B2 (en) | Medicinal compounds | |
US7402598B2 (en) | Arylethanolamine β2-adrenoreceptor agonist compounds | |
US7271197B2 (en) | Phenethanolamine derivatives | |
WO2004039766A1 (fr) | Derives de phenylethanolamine pour le traitement de maladies respiratoires | |
US20070135490A1 (en) | Phenetanolamine derivatives | |
US7294650B2 (en) | Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders | |
WO2004039762A1 (fr) | Derives de phenethanolamine permettant de traiter des maladies des voies respiratoires | |
WO2004022547A1 (fr) | Derives de phenethanolamine, et leur utilisation pour le traitement des maladies respiratoires | |
WO2005058299A1 (fr) | Derives de phenethanolamine destines au traitement de maladies respiratoires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |